Investigational drug · Phase 2
HB0034
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Generalized Pustular Psoriasis (GPP).
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "HB0034"
First trial start
2024
Feb 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HB0034", any sponsor or status.
Conditions studied
As listed on its trial records.
- Generalized Pustular Psoriasis (GPP)
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "HB0034" as an intervention, largest first.
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT06716151 · 60 participants (planned) · Start Dec 6, 2024 · Primary completion Nov 20, 2025
Drug: HB0034; HB0034 matching placebo · For: Healthy
Sites: Jinan, China
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT05064345 · 56 participants · Start Dec 3, 2021 · Primary completion Sep 1, 2022
Drug: HB0034; Placebo · For: Healthy
Sites: Auckland, New Zealand
- Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular PsoriasisPivotal-lookingStatus unknown
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT06477536 · 33 participants (planned) · Start Sep 2, 2024 · Primary completion Dec 30, 2025
Drug: HB0034 · For: Generalized Pustular Psoriasis
Sites: Beijing, China; Hangzhou, China · 3 sites in all
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT06231381 · 33 participants (planned) · Start Feb 29, 2024 · Primary completion Feb 13, 2025
Drug: HB0034 · For: Generalized Pustular Psoriasis (GPP)
Sites: Beijing, China; Shanghai, China
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT05460455 · 30 participants · Start Oct 13, 2022 · Primary completion Jun 9, 2023
Drug: Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo · For: Healthy
Sites: Auckland, New Zealand
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT05512598 · 9 participants · Start Nov 6, 2022 · Primary completion Nov 15, 2023
Drug: HB0034 · For: Generalized Pustular Psoriasis
Sites: Shandong, China
Newest research
PubMed records naming it or its code names, newest first.
- Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency.
Ma X, Zhang S, Ren X, et al. · Front Immunol 2024
- New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors.
Vilaça J, Yilmaz O, Torres T · Pharmaceutics 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.